nach oben

Endocrine

Erschienen in:

01.10.2012 | Mini Review

Points of integration between the intracellular energy sensor AMP-activated protein kinase (AMPK) activity and the somatotroph axis function

verfasst von: Giovanni Tulipano, Lara Faggi, Valeria Sibilia, Andrea Giustina

Erschienen in: Endocrine | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

AMP-activated protein kinase (AMPK), an enzyme functioning as a cellular sensor of low energy, stores and promotes adaptive changes in growth, differentiation, and metabolism. While AMPK is primarily thought of as a regulator of systemic metabolism, it has been clearly established that it also has a role in the regulation of cell growth and may be a therapeutic target for proliferative disorders. Growth hormone (GH) secretion from the anterior pituitary and GH-induced synthesis and release of insulin-like-growth-factor-1 (IGF-1) from the liver determine linear growth before puberty. Actually, GH and IGF-1 are potent growth factors affecting cell growth and differentiation in different tissues, and still have anabolic functions and serve as essential regulators of fuel metabolism in adulthood, as well. A variety of peripheral hormonal and metabolic signals regulate GH secretion either by acting directly on the anterior pituitary and/or modulating GH-releasing hormone or somatostatin release from the hypothalamus. Actually, intracellular transduction of endocrine and metabolic signals regulating somatotroph function is still debated. Based on the previously summarized contents, the aim of the present work has been to review currently available data suggesting a role of AMPK in the interplay between GH axis activity and metabolic functions.

D.G. Hardie, AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8, 774–785 (2007)PubMedCrossRef

S.A. Hawley, J. Boudeau, J.L. Reid, K.J. Mustard, L. Udd, T.P. Mäkelä, D.R. Alessi, D.G. Hardie, Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28 (2003)PubMedCrossRef

A. Woods, S.R. Johnstone, K. Dickerson, F.C. Leiper, L.G. Fryer, D. Neumann, U. Schlattner, T. Wallimann, M. Carlson, D. Carling, LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13, 2004–2008 (2003)PubMedCrossRef

M.C. Towler, G.D. Hardie, AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 100, 328–341 (2007)PubMedCrossRef

S.P. Davies, N.R. Helps, P.T. Cohen, D.G. Hardie, 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C{alpha} and native bovine protein phosphatase-2AC. FEBS Lett. 377, 421–425 (1995)PubMedCrossRef

C.T. Lim, B. Kola, M. Korbonits, AMPK as a mediator of hormonal signalling. J. Mol. Endocrinol. 44, 87–97 (2009)PubMedCrossRef

S. Sangiao-Alvarellos, L. Varela, M.J. Vazquez, K. Da Boit, S.A. Saha, F. Cordido, C. Dieguez, M. Lopez, Influence of ghrelin and growth hormone deficiency on AMP-activated protein kinase and hypothalamic lipid metabolism. J. Neuroendocrinol. 22, 543–556 (2010)PubMedCrossRef

R.L. Hurley, K.A. Anderson, J.M. Franzone, B.E. Kemp, A.R. Means, L.A. Witters, The Ca²⁺/calmoldulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 280, 29060–29066 (2005)PubMedCrossRef

M. Lu, Q. Tang, J.M. Olefsky, P.L. Mellon, N.J. Webster, Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in L(beta)T2 gonadotropes. Mol. Endocrinol. 22, 760–771 (2008)PubMedCrossRef

10.

Z. Luo, Y. Zhang, F. Li, J. He, H. Ding, L. Yan, H. Cheng, Resistin induces insulin resistance in both AMPK dependent and AMPK independent mechanisms in HepG2 cells. Endocrine 36, 60–69 (2009)PubMedCrossRef

11.

X. Xiao, Y. Dong, J. Zhong, R. Cao, X. Zhao, G. Wen, J. Liu, Adiponectin protects endothelial cells from the damages induced by the intermittent high levels of glucose. Endocrine 40, 386–393 (2011)PubMedCrossRef

12.

X.B. Cheng, J.P. Wen, Y. Yang, J. Yang, G. Ning, X.Y. Li, GnRH secretion is inhibited by adiponectin through activation of AMPK-activated protein kinase and extracellular signal-regulated kinase. Endocrine 39, 6–12 (2011)PubMedCrossRef

13.

M. Xie, D. Zhang, J.R. Dyck, Y. Li, H. Zhang, M. Morishima, D.L. Mann, G.E. Taffet, A. Baldini, D.S. Khoury, M.D. Schneider, A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl. Acad. Sci. USA 103, 17378–17383 (2006)PubMedCrossRef

14.

A. Suzuki, G. Kusakai, A. Kishimoto, Y. Shimojo, T. Ogura, M.F. Lavin, H. Esumi, IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem. Biophys. Res. Commun. 324, 986–992 (2004)PubMedCrossRef

15.

E. Tomas, T.S. Tsao, A.K. Saha, H.E. Murrey, C. Zhang Cc, S.I. Itani, H.F. Lodish, N.B. Ruderman, Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 99, 16309–16313 (2002)PubMedCrossRef

16.

W.W. Winder, D.G. Hardie, Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol. 270, E299–E304 (1996)PubMed

17.

M.E. Young, G.K. Radda, B. Leighton, Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR—an activator of AMP-activated protein kinase. FEBS Lett. 382, 43–47 (1996)PubMedCrossRef

18.

G.R. Steinberg, S.B. Jorgensen, The AMP-activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity. Mini-Rev. Med. Chem. 7, 521–528 (2007)CrossRef

19.

V. Locatelli, A. Torsello, Pyruvate and satiety: can we fool the brain? Endocrinology 146, 1–2 (2005)PubMedCrossRef

20.

M.F. McCarty, Chronic activation of AMP-activated kinase as a strategy for slowing aging. Med. Hypotheses 63, 334–339 (2004)PubMedCrossRef

21.

M.M. Mihaylova, R.J. Shaw, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016–1023 (2011)PubMedCrossRef

22.

M. Josie, M. Evans, Metformin and reduced risk of cancer in diabetic patients. Br. Med. J. 330, 1304–1305 (2005)CrossRef

23.

H. Motoshima, B.J. Goldstein, M. Igata, E. Araki, AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. 574, 63–71 (2006)PubMedCrossRef

24.

M. Zakikhani, R. Dowling, I.G. Fantus, N. Sonenberg, M. Pollak, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269–10273 (2006)PubMedCrossRef

25.

T.K. Sengupta, G.M. Leclerc, T.T. Hsieh-Kinser, G.J. Leclerc, I. Singh, J.C. Barredo, Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol. Cancer 6, 46–58 (2007)PubMedCrossRef

26.

M. Buzzai, R.G. Jones, R.K. Amaravadi, J.J. Lum, R.J. DeBerardinis, F. Zhao, B. Villet, C.B. Thompson, Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745–6752 (2007)PubMedCrossRef

27.

H.U. Park, S. Suy, M. Danner, V. Dailey, Y. Zhang, H. Li, D.R. Hyduke, B.T. Collins, G. Gagnon, B. Kallakury, D. Kumar, M.L. Brown, A. Fornace, A. Dritschilo, S.P. Collins, AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol. Cancer Ther. 8, 733–741 (2009)PubMedCrossRef

28.

J.M. Corton, J.G. Gillespie, S.A. Hawley, D.G. Hardie, 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558–565 (1995)PubMedCrossRef

29.

R. Rattan, S. Giri, A.K. Singh, I. Singh, 5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 280, 39582–39593 (2005)PubMedCrossRef

30.

Y. Gao, Y. Zhou, A. Xu, D. Wu, Effects of an AMP-activated protein kinase inhibitor, compound C, on adipogenic differentiation of 3T3-L1 cells. Biol. Pharm. Bull. 31, 1716–1722 (2008)PubMedCrossRef

31.

I. Kanazawa, T. Yamaguchi, S. Yano, M. Yamauchi, T. Sugimoto, Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3E1 cells through endothelial NOS and BMP-2 expression. Am. J. Physiol. Endocrinol. Metab. 296, 139–146 (2009)CrossRef

32.

G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, D.E. Moller, Role of AMPK-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001)PubMed

33.

E.E. Müller, V. Locatelli, D. Cocchi, Neuroendocrine control of growth hormone secretion. Physiol. Rev. 79, 511–607 (1999)PubMed

34.

W.B. Wehrenberg, P.J. Bergman, L. Stagg, J. Ndon, A. Giustina, Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 127, 2705–2708 (1990)PubMedCrossRef

35.

G. Tulipano, J.E. Taylor, H.A. Halem, R. Datta, J.Z. Dong, M.D. Culler, I. Bianchi, D. Cocchi, A. Giustina, Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Pituitary 10, 267–274 (2007)PubMedCrossRef

36.

A. Giustina, J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717–797 (1998)PubMedCrossRef

37.

A. Giustina, W.B. Wehrenberg, Influence of thyroid hormones on the regulation of growth hormone secretion. Eur. J. Endocrinol. 133, 646–653 (1995)PubMedCrossRef

38.

M. Christ-Crain, B. Kola, F. Lolli, C. Fekete, D. Seboek, G. Wittmann, D. Feltrin, S.C. Igreja, S. Ajodha, J. Harvey-White, G. Kunos, B. Müller, F. Pralong, G. Aubert, G. Arnaldi, G. Giacchetti, M. Boscaro, A.B. Grossman, M. Korbonits, AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 22, 1673–1683 (2008)CrossRef

39.

M. Lopez, R. Lage, A.K. Saha, D. Perez-Tilve, M.J. Vazquez, L. Varela, S. Sangiao-Alvarellos, S. Tovar, K. Raghay, S. Rodriguez-Cuenca, R.M. Deoliveira, T. Castaneda, R. Datta, J.Z. Dong, M. Culler, M.W. Sleeman, C.V. Alvarez, R. Gallego, C.J. Lelliot, D. Carling, M.H. Tschop, C. Dieguez, A. Vidal-Puig, Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 7, 389–399 (2008)PubMedCrossRef

40.

Z.B. Andrews, Z.W. Liu, N. Wallingford, D.M. Erion, E. Borok, J.M. Friedman, M.H. Tschop, M. Shanabrough, G. Cline, G.I. Shulman, A. Coppola, X.B. Gao, T.L. Horvath, S. Diano, UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals. Nature 454, 846–851 (2008)PubMedCrossRef

41.

M. Pollak, Insulin and Insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915–928 (2008)PubMedCrossRef

42.

I. Chopra, H.F. Li, H. Wang, K.A. Webster, Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle. Diabetologia. doi:10.1007/s00125-011-2407-y (2012)

43.

A.A. Hayashi, C.G. Proud, The rapid inactivation of protein synthesis by growth hormone requires signaling through mTOR. Am. J. Physiol. Endocrinol. Metab. 292, E1647–E1655 (2007)PubMedCrossRef

44.

C. Beauloye, A.S. Marsin, L. Bertrand, U. Krause, D.G. Hardie, J.L. Vanoverschelde, L. Hue, Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS Lett. 505, 348–352 (2001)PubMedCrossRef

45.

S. Kovacic, C.L. Soltys, A.J. Barr, I. Shiojima, K. Walsh, J.R. Dyck, Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J. Biol. Chem. 278, 39422–39427 (2003)PubMedCrossRef

46.

K. To, H. Yamaza, T. Komatsu, T. Hayashida, H. Hayashi, H. Toyama, T. Chiba, Y. Higami, I. Shimokawa, Down-regulation of AMP-activated protein kinase by calorie restriction in rat liver. Exp. Gerontol. 42, 1063–1071 (2007)PubMedCrossRef

47.

K.A. Al-Regaiey, M.M. Masternak, M. Bonkowski, L. Sun, A. Bartke, Long-lived growth hormone receptor knockout mice: interaction of reduced insulin-like growth factor 1/insulin signaling and caloric restriction. Endocrinology 2005(146), 851–860 (2005)

48.

Z. Wang, M.M. Masternak, K.A. Al-Regaiey, A. Bartke, Adipocytokines and the regulation of lipid metabolism in growth hormone transgenic and calorie-restricted mice. Endocrinology 148, 2845–2853 (2007)PubMedCrossRef

49.

B. Olsson, Y.M. Bohlooly, S.M. Fitzgerald, F. Frick, A. Ljungberg, B. Ahren, J. Tornell, G. Bergstrom, J. Oscarsson, Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology 146, 920–930 (2005)PubMedCrossRef

50.

S. Sangiao-Alvarellos, M.J. Vazquez, L. Varela, R. Nogueiras, A.K. Saha, F. Cordido, M. Lopez, C. Dieguez, Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology 150, 4562–4574 (2009)PubMedCrossRef

51.

G. Tulipano, M. Giovannini, M. Spinello, V. Sibilia, A. Giustina, D. Cocchi, AMP-activated protein kinase regulates normal rat somatotroph cell function and growth of rat pituitary adenomatous cells. Pituitary 14, 242–252 (2011)PubMedCrossRef

52.

G. Tulipano, D. Soldi, M. Bagnasco, M.D. Culler, J.E. Taylor, D. Cocchi, A. Giustina, Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143, 1218–1224 (2002)PubMedCrossRef

53.

M.S. Lewitt, Stimulation of IGF-binding protein-1 secretion by AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 282, 1126–1131 (2001)PubMedCrossRef

54.

S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509–1517 (2009)PubMedCrossRef

55.

A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S.W. Lamberts, P.P. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)PubMedCrossRef

56.

S. Melmed, Acromegaly pathogenesis and treatment. J. Clin. Invest. 119, 3189–3202 (2009)PubMedCrossRef

57.

A. Gorshtein, H. Rubinfeld, E. Kendler, M. Theodoropoulou, V. Cerovac, G.K. Stalla, Z.R. Cohen, M. Hadani, I. Shimon, Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr. Relat. Cancer 16, 1017–1027 (2009)PubMedCrossRef

58.

G. Tulipano, L. Faggi, M. Losa, P. Mortini, M. Spinello, D. Cocchi, A. Giustina, Effects of the combined treatment with AMPK activator and somatostatin-14 on hormone secretion and cell proliferation in cultured GH-secreting pituitary tumor cells, in International Congress of Endocrinology/European congress of Endocrinology 2012, Florence, May 5–9 (2012)

59.

O. Ali, S. Banerjee, D.F. Kelly, P.D.K. Lee, Management of type 2 diabetes mellitus associated with pituitary gigantism. Pituitary 10, 359–364 (2007)PubMedCrossRef

60.

L. Fontana, The scientific basis of caloric restriction leading to longer life. Curr. Opin. Gastroenterol. 25, 144–150 (2009)PubMedCrossRef

61.

A. Bartke, Pleiotropic effects of growth hormone signaling in aging. Trends. Endocrinol. Metab. 22, 437–442 (2011)PubMedCrossRef

Titel: Points of integration between the intracellular energy sensor AMP-activated protein kinase (AMPK) activity and the somatotroph axis function
verfasst von: Giovanni Tulipano
Lara Faggi
Valeria Sibilia
Andrea Giustina
Publikationsdatum: 01.10.2012
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-012-9732-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism

Meta-analysis of association studies between five candidate genes and type 2 diabetes in Chinese Han population

Ectopic posterior pituitary causing hyperprolactinemia

Changes in serum 25-hydroxyvitamin D and cholecalciferol after one whole-body exposure in a commercial tanning bed: a randomized study

Biomechanical properties of the mid-shaft femur in middle-aged hypophysectomized rats as assessed by bending test